-
Mashup Score: 19
– All 12 patients who received the full dose of VX-880 as a single infusion demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90 – – All patients achieved ADA -recommended target HbA1c levels 70% time-in-range (70-180 mg/dL), and 11 of 12 patients…
Source: news.vrtx.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 51Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a) - 9 month(s) ago
Study demonstrated highly significant and sustained reductions in Lp(a) to week 48 Data support advancing zerlasiran into phase 3 with 300 mg dose Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced positive topline 48-week data from the ALPACAR-360 phase 2 study of zerlasiran (SLN360) in 178 subjects with baseline lipoprotein(a), or Lp(a), levels at or over 125 nmol/L at high risk of atherosclerotic cardiovascular disease (ASCVD) events. Zerlasiran is a siRNA (short interfering RNA) designed to lower the body’s production of Lp(a), a key genetic risk factor for cardiovascular disease affecting up to 20% of the world’s population. In the double-blind placebo-controlled treatment period, zerlasiran was administered at 300 mg subcutaneously every 16 or 24 weeks and 450 mg every 24 weeks to patients with
Source: silence-therapeutics.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 51Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a) - 9 month(s) ago
Study demonstrated highly significant and sustained reductions in Lp(a) to week 48 Data support advancing zerlasiran into phase 3 with 300 mg dose Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced positive topline 48-week data from the ALPACAR-360 phase 2 study of zerlasiran (SLN360) in 178 subjects with baseline lipoprotein(a), or Lp(a), levels at or over 125 nmol/L at high risk of atherosclerotic cardiovascular disease (ASCVD) events. Zerlasiran is a siRNA (short interfering RNA) designed to lower the body’s production of Lp(a), a key genetic risk factor for cardiovascular disease affecting up to 20% of the world’s population. In the double-blind placebo-controlled treatment period, zerlasiran was administered at 300 mg subcutaneously every 16 or 24 weeks and 450 mg every 24 weeks to patients with
Source: silence-therapeutics.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 2
Atherosclerotic cardiovascular diseases (ASCVD), including myocardial infarction, stroke, and peripheral arterial disease, remain major causes of death in LATAM. The primary strategy for preventing ASCVD involves averting the accumulation of cholesterol-containing atherogenic lipoproteins in the vessel wall. Extensive, well-designed, placebo-controlled studies have demonstrated that lowering LDL cholesterol levels reduces cardiovascular events. Given the significant number of patients requiring lipid-lowering therapy, a crucial question arises: Are we effectively treating LDL cholesterol levels to attain the desired goals? In this webinar, we will delve into dyslipidemia as a cardiovascular risk in LATAM. We will discuss LDL cholesterol goals recommended by recent guidelines, focusing on the barriers hindering the achievement of these goals. Moreover, we will emphasize the necessity of identifying the main barriers to getting patients to their goals and controlling cardiovascular risk
Source: us02web.zoom.usCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 20Episódio 16 - O desafio da epidemia global de obesidade e opções terapêuticas para enfrentá-lo by DA Podcast - 1 year(s) ago
Tema: O desafio da epidemia global de obesidade e opções terapêuticas para enfrentá-lo Apresentado por: Dr. Sergio Emanuel Kaiser – Coordenador de Relações Internacionais e Comunicação SBC-DA e Prof. Jose Francisco Kerr Saraiva – Presidente SBC-DA
Source: podcasters.spotify.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 17Effects of Cuff Size on the Accuracy of Blood Pressure Readings - 1 year(s) ago
This randomized crossover trial aims to determine the effect of using a regular blood pressure cuff vs an appropriately sized blood pressure cuff on automated blood pressure readings.
Source: jamanetwork.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 2Dólar abre em queda nesta terça-feira - 1 year(s) ago
Principal índice da bolsa de valores subiu 0,68%, aos 131.084 pontos, novo recorde histórico. Já a moeda norte-americana caiu 0,65%, cotada a R$ 4,9047.
Source: g1.globo.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 1Bayer cancels asundexian phase III study program - 1 year(s) ago
Germany’s Bayer AG said on Sunday it is cancelling a phase III study program to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor.
Source: www.reuters.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 3Javier Milei é eleito presidente da Argentina com pauta ultraliberal e discurso radical antipolítica - 1 year(s) ago
Economista venceu Sergio Massa no 2º turno e tomará posse em dezembro para 4 anos de mandato. Entre suas propostas estão dolarizar a economia e fechar o Banco Central.
Source: g1.globo.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 4European Atherosclerosis Society on LinkedIn: With just a little more than a week to go, make sure to sign up for our… - 1 year(s) ago
With just a little more than a week to go, make sure to sign up for our upcoming webinar on November 15. Dr Peter Libby will discuss the significance of…
Source: www.linkedin.comCategories: General Medicine News, CardiologistsTweet
Amazing! Are we heading toward cure of type I #diabetes? @AliceYYCheng @AmarPut @GoggleDocs #CardioTwitter #MedTwitter https://t.co/uwgFBSUwnG